Agenus Inc. — Form 10-Q summary
Business context and period. This unaudited filing covers the quarter and six months ended June 30, 2015. Agenus is an immunology-focused biotechnology company developing checkpoint-modulating antibodies, heat shock protein vaccines, and vaccine adjuvants. Its product programs were primarily preclinical or clinical-stage; reported revenue was principally from licenses and collaborations, not product sales.
Key financial results
| Metric | Three months ended June 30, 2015 | Six months ended June 30, 2015 |
|---|---|---|
| Revenue | $6.38 million | $10.33 million |
| Research and development expense | $24.77 million | $33.99 million |
| General and administrative expense | $8.02 million | $13.50 million |
| Operating loss | $33.20 million | $51.49 million |
| Net loss | $40.41 million | $59.15 million |
| Net loss attributable to common stockholders | $40.46 million; $0.53 per share | $59.25 million; $0.83 per share |
For the six months, revenue increased from $3.79 million in 2014, while net loss widened from $8.40 million. R&D expense rose from $9.70 million, reflecting advancement of checkpoint-modulator programs, higher headcount, and a $13.2 million Celexion in-process R&D charge. G&A expense increased from $11.29 million. There was no product gross-margin disclosure; the company remained loss-making.
Six-month net cash used in operating activities was $9.57 million, versus $19.62 million in 2014. Cash and cash equivalents were $124.66 million at June 30, with $14.98 million of short-term investments, or $139.64 million combined. Current assets were $146.28 million and current liabilities $25.32 million. Debt principal outstanding was $14.1 million; the new subordinated notes bear 8% interest and mature in February 2018. The filing reports $87.19 million in stockholders’ equity and an accumulated deficit of $750.46 million.
Material changes and notable items
- Incyte collaboration and stock investment generated $60 million in aggregate proceeds: a $25 million upfront collaboration payment and a $35 million purchase of Agenus shares. The collaboration initially covers GITR, OX40, LAG-3, and TIM-3 programs, with shared costs and profits for two programs and cost reimbursement, potential milestones, and royalties for two others.
- A May 2015 public offering raised approximately $75 million net. Common shares issued increased from 62.72 million at December 31, 2014 to 84.26 million at June 30, 2015, creating substantial dilution.
- Agenus acquired Celexion antibody-discovery assets for approximately $13.2 million in total consideration; because the acquired R&D had no alternative future use, the amount was expensed. It also paid a $20 million contingent milestone related to the 4-Antibody acquisition.
- Contingent purchase-price consideration fair-value adjustments contributed $14.32 million of operating expense in the six-month period. Non-operating expense was $6.70 million, compared with $10.58 million of non-operating income in the 2014 period; the 2015 amount included fair-value effects, foreign exchange loss, and debt-extinguishment loss.
Outlook, commentary, and risks
Management believed available working capital at June 30 would fund operations into 2017, but expected significant losses to continue and said it would seek additional financing before funds were depleted. The reported first-half operating cash use benefited from the Incyte upfront payment and was not considered indicative of future cash use. Management may reduce spending or scale back programs to preserve liquidity; additional financing may not be available on favorable terms or at all.
Agenus planned to file two INDs for GITR and CTLA-4 candidates in 2015 and anticipated first clinical trials from the Incyte programs in 2016. These were forward-looking plans, not assured outcomes. Prophage’s potential Phase 3 GBM development depended on partnership or alternative financing. QS-21-related launches were anticipated by the company in the 2017 timeframe, contingent on partners’ clinical, regulatory, manufacturing, and commercialization success.
Key risks include clinical and regulatory failure or delay, reliance on Incyte and other licensees, uncertain future collaboration and royalty income, continued capital needs and dilution, 8% debt obligations, manufacturing and trial-enrollment challenges, competition, and intellectual-property risks. The company disclosed no hedging strategy for its primary foreign-currency exposures. Disclosure controls were deemed effective, with no material second-quarter change in internal control over financial reporting.
Important facts for investors to verify
- Whether the planned 2015 IND filings and anticipated 2016 clinical starts occurred, and the related development costs and partner commitments.
- Cash runway versus actual operating cash use, particularly after excluding collaboration upfront payments and other nonrecurring cash flows.
- Progress, enrollment, funding, and partnership status for Prophage and the prospects for QS-21 partner programs.
- Terms and potential dilution from outstanding equity plans, warrants, the at-the-market facility, and remaining acquisition consideration.
- Changes in contingent liabilities and the assumptions behind their fair-value estimates, including milestone probabilities and potential royalty receipts.